Arcutis Biotherapeutics Stock Forecast
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:55 PM ET
ARQT analyst consensus
Consensus (7 analysts)
none
Avg. price target
$37.00+53.62%
- Strong buy 2
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Arcutis Biotherapeutics (2026-10-07), 6 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $37.00, with a high estimate of $40.00 and a low estimate of $34.00. The average target implies upside of 53.6% from the current price of $24.09.
The spread between the highest and lowest targets is 17.6%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ARQT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 29% |
| Buy | 4 | 57% |
| Hold | 1 | 14% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $34.00 | +41.17% |
| Average target | $37.00 | +53.62% |
| High target | $40.00 | +66.08% |